Chief Executive Officer
Catherine Marle is the Chief Executive Officer of TRIO. She holds a Master of Science degree in biochemistry and immunology and a post-graduate diploma in molecular biology. Catherine has nearly 30 years of leadership and experience in global drug development, translational research and alliance management.
She has worked with pharmaceutical and biotech companies, as well as contract research organizations to bring new products on the market in a range of therapeutic areas including oncology, CVS, CNS, and rare diseases.
She brings her expertise and passion to support the development of new drugs with high scientific interest and the most chance of being successful. She works with TRIO teams across the globe to expand the treatment options available to cancer patients.